980 related articles for article (PubMed ID: 21988181)
1. Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides.
Li J; Pei H; Zhu B; Liang L; Wei M; He Y; Chen N; Li D; Huang Q; Fan C
ACS Nano; 2011 Nov; 5(11):8783-9. PubMed ID: 21988181
[TBL] [Abstract][Full Text] [Related]
2. Design and development of nanosized DNA assemblies in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells.
Mohri K; Nishikawa M; Takahashi N; Shiomi T; Matsuoka N; Ogawa K; Endo M; Hidaka K; Sugiyama H; Takahashi Y; Takakura Y
ACS Nano; 2012 Jul; 6(7):5931-40. PubMed ID: 22721419
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice.
Nishikawa M; Mizuno Y; Mohri K; Matsuoka N; Rattanakiat S; Takahashi Y; Funabashi H; Luo D; Takakura Y
Biomaterials; 2011 Jan; 32(2):488-94. PubMed ID: 20932569
[TBL] [Abstract][Full Text] [Related]
4. CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells.
Zhu FG; Marshall JS
J Leukoc Biol; 2001 Feb; 69(2):253-62. PubMed ID: 11272276
[TBL] [Abstract][Full Text] [Related]
5. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
Li Y; Kandimalla ER; Yu D; Agrawal S
Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann E; Vollmer J
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
[TBL] [Abstract][Full Text] [Related]
8. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines.
Lipford GB; Sparwasser T; Bauer M; Zimmermann S; Koch ES; Heeg K; Wagner H
Eur J Immunol; 1997 Dec; 27(12):3420-6. PubMed ID: 9464831
[TBL] [Abstract][Full Text] [Related]
10. Self-Assembled DNA Immunonanoflowers as Multivalent CpG Nanoagents.
Zhang L; Zhu G; Mei L; Wu C; Qiu L; Cui C; Liu Y; Teng IT; Tan W
ACS Appl Mater Interfaces; 2015 Nov; 7(43):24069-74. PubMed ID: 26440045
[TBL] [Abstract][Full Text] [Related]
11. The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity.
Rattanakiat S; Nishikawa M; Funabashi H; Luo D; Takakura Y
Biomaterials; 2009 Oct; 30(29):5701-6. PubMed ID: 19604576
[TBL] [Abstract][Full Text] [Related]
12. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
13. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides.
Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y
J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages.
Yasuda S; Yoshida H; Nishikawa M; Takakura Y
Mol Pharm; 2010 Apr; 7(2):533-42. PubMed ID: 20047296
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
16. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis.
Deng GM; Nilsson IM; Verdrengh M; Collins LV; Tarkowski A
Nat Med; 1999 Jun; 5(6):702-5. PubMed ID: 10371511
[TBL] [Abstract][Full Text] [Related]
17. Decreased intracellular TLR9 confers hyporesponsiveness of RAW264.7 cells to subsequent CpG ODN challenge.
Wei L; Hong Z; Jiang Z; Guofu D; Hongwei C; Liangxi W; Yongling L; Bin L; Ping L
Int Immunopharmacol; 2006 Jun; 6(6):935-46. PubMed ID: 16644479
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Stimulation of Toll-Like Receptor 9 by CpG Oligodeoxynucleotides Incorporated Into Polypod-Like DNA Nanostructures.
Takahashi Y; Maezawa T; Araie Y; Takahashi Y; Takakura Y; Nishikawa M
J Pharm Sci; 2017 Sep; 106(9):2457-2462. PubMed ID: 28385547
[TBL] [Abstract][Full Text] [Related]
19. The immunostimulatory activity of phosphorothioate CpG oligonucleotides is affected by distal sequence changes.
Roberts TL; Dunn JA; Sweet MJ; Hume DA; Stacey KJ
Mol Immunol; 2011 Apr; 48(8):1027-34. PubMed ID: 21324527
[TBL] [Abstract][Full Text] [Related]
20. Self-assembly of poly-adenine-tailed CpG oligonucleotide-gold nanoparticle nanoconjugates with immunostimulatory activity.
Chen N; Wei M; Sun Y; Li F; Pei H; Li X; Su S; He Y; Wang L; Shi J; Fan C; Huang Q
Small; 2014 Jan; 10(2):368-75. PubMed ID: 23963797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
